Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1541 to 1550 of 2617 total matches.

Citalopram, Escitalopram and the QT Interval

   
The Medical Letter on Drugs and Therapeutics • Jul 22, 2013  (Issue 1421)
dosage of the drug because of a dose-related increase in the QT interval.1 Since then, some of our ...
In 2011, the FDA asked the manufacturers of the selective serotonin reuptake inhibitor (SSRI) citalopram (Celexa, and generics) to lower the maximum daily dosage of the drug because of a dose-related increase in the QT interval. Since then, some of our readers have asked whether escitalopram (Lexapro, and generics), the active enantiomer of citalopram, could have the same effect.
Med Lett Drugs Ther. 2013 Jul 22;55(1421):59 |  Show IntroductionHide Introduction

Ocriplasmin (Jetrea) for Vitreomacular Adhesion

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 2013  (Issue 1422)
formation, and retinal tears or detachment.1 MECHANISM OF ACTION — Ocriplasmin is a recombinant selective ...
Ocriplasmin (Jetrea – ThromboGenics) was recently approved by the FDA as an intravitreal injection for treatment of symptomatic vitreomacular adhesion. It is the first drug to be approved in the US for this indication.
Med Lett Drugs Ther. 2013 Aug 5;55(1422):63-4 |  Show IntroductionHide Introduction

Electronic Cigarettes

   
The Medical Letter on Drugs and Therapeutics • Nov 11, 2013  (Issue 1429)
among smokers, but also among non-smokers.1,2 THE DEVICES — E-cigarettes are battery-operated devices ...
Electronic cigarettes, also called e-cigarettes, are advertised as a safer, more convenient, and socially acceptable alternative to smoking tobacco cigarettes. Widely available in retail stores and on the Internet, their use has been increasing over recent years, primarily among smokers, but also among non-smokers.
Med Lett Drugs Ther. 2013 Nov 11;55(1429):89-90 |  Show IntroductionHide Introduction

In Brief: Pancreatic Enzyme Replacement Products

   
The Medical Letter on Drugs and Therapeutics • Oct 09, 2017  (Issue 1531)
IN BRIEF Pancreatic Enzyme Replacement Products Table 1. FDA-Approved Pancreatic Enzyme ...
Pancreatic enzyme replacement products have been used for years to improve digestion in patients with exocrine pancreatic insufficiency (EPI). These products were initially marketed before formal FDA approval was required; in 1991, however, the FDA told all manufacturers of pancreatic enzyme replacement products that they would have to submit a new drug application by April 2010 in order to keep their products on the market.EPI is a chronic disorder characterized by a deficiency of exocrine pancreatic enzymes, which results in malabsorption, steatorrhea, and weight loss. Irreversible EPI is...
Med Lett Drugs Ther. 2017 Oct 9;59(1531):170 |  Show IntroductionHide Introduction

Firvanq - Vancomycin Oral Solution

   
The Medical Letter on Drugs and Therapeutics • Jul 16, 2018  (Issue 1551)
1. SN Bass et al. Comparison of oral vancomycin capsule and solution for treatment of initial ...
The FDA has approved vancomycin oral solution (Firvanq – Cutis Pharma) for treatment of Clostridium difficile-associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (MRSA).
Med Lett Drugs Ther. 2018 Jul 16;60(1551):122 |  Show IntroductionHide Introduction

Capmatinib (Tabrecta) for NSCLC (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023  (Issue 1674)
for the same indication in 2020 based on initial overall response rates and duration of response.1 ADVERSE ...
The FDA has granted regular approval to the oral kinase inhibitor capmatinib (Tabrecta – Novartis) for treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping. MET exon 14 skipping mutations occur in 3-4% of NSCLC cases. The drug received accelerated approval for the same indication in 2020 based on initial overall response rates and duration of response.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e65-6   doi:10.58347/tml.2023.1674d |  Show IntroductionHide Introduction

Comparison Table: Some Drugs for Plaque Psoriasis (online only)

   
The Medical Letter on Drugs and Therapeutics • Sep 30, 2024  (Issue 1712)
▶ Suspension and foam can be used on the scalpComparison Table. Some Drugs for Plaque Psoriasis (continued)1 ...
View the Comparison Table: Some Drugs for Plaque Psoriasis
Med Lett Drugs Ther. 2024 Sep 30;66(1712):e160-6   doi:10.58347/tml.2024.1712b |  Show IntroductionHide Introduction

New Copper IUD

   
The Medical Letter on Drugs and Therapeutics • Feb 26, 1988  (Issue 760)
, those 20 to 24 years old had a rate of 3.2, and those 25 years old or older had a rate of 1.0. The one ...
The copper T 380A (ParaGard - GynoPharma), a new intrauterine contraceptive device (IUD) soon to be marketed in the USA, will be one of only two IUDs available in this country. Progestasert (Alza), which gradually releases progesterone (Medical Letter, 18:65, 1976), is the other.
Med Lett Drugs Ther. 1988 Feb 26;30(760):25-6 |  Show IntroductionHide Introduction

Pentamidine Aerosol To Prevent Pneumocystis Carinii Pneumonia

   
The Medical Letter on Drugs and Therapeutics • Oct 06, 1989  (Issue 802)
200 cells/mm 3 or less than 20% of total lymphocytes (H Masur et al, Ann Intern Med, 111:223, Aug 1 ...
Pneumocystis carinii pneumonia (PCP) occurs in nearly 80% of patients with the acquired immune deficiency syndrome (AIDS) and is a common cause of morbidity and mortality. Oral trimethoprim-sulfamethoxazole (Bactrim; and others), intravenous isethionate (Pentam 300) and other systemic drugs have been used to prevent PCP, but in AIDS patients, all of these agents can occasionally cause severe adverse effects (Medical Letter, 30:94, 1988). Recently, the US Food and Drug Administration approved marketing of aerosolized pentamidine isethionate (NebuPent - LyphoMed) for this indication. Another...
Med Lett Drugs Ther. 1989 Oct 6;31(802):91-2 |  Show IntroductionHide Introduction

Clozapine for Schizophrenia

   
The Medical Letter on Drugs and Therapeutics • Jan 12, 1990  (Issue 809)
blockade, clozapine has serotonergic, adrenergic, histaminergic (H 1 ) and cholinergic blocking activity ...
Clozapine (Clozaril - Sandoz), a dibenzodiazepine antipsychotic drug that has been available in Europe for many years, was recently approved for marketing by the US Food and Drug Administration. Because of its toxicity, the labeling for clozapine recommends using the drug only for schizophrenic patients who have not responded adequately to standard antipsychotic drugs or have had intolerable adverse effects.
Med Lett Drugs Ther. 1990 Jan 12;32(809):3-4 |  Show IntroductionHide Introduction